|
| Press Releases |
|
 |
|
| Friday, May 25, 2018 |
|
|
Eisai and Merck & Co. Provide Update on Supplemental New Drug Application (sNDA) for Lenvatinib |
| The FDA has indicated that the extension of the Prescription Drug User Fee Act (PDUFA) date is needed to allow additional time for review of the application. more info >> |
|
| Wednesday, May 23, 2018 |
|
|
Eisai and Purdue Pharma to Present Latest Phase I Clinical Data on Lemborexant at 32nd Annual Sleep Meeting |
| Eisai Co., Ltd. and Purdue Pharma L.P. today announced they will present the latest data from two key Phase I clinical studies (Study 108 and Study 106). more info >> |
|
| Thursday, May 17, 2018 |
|
|
Eisai to Present Data on Oncology Pipeline and Products at 54th ASCO Annual Meeting |
| Eisai Co., Ltd. announced today that presentations on a series of abstracts highlighting updates regarding its in-house discovered multiple receptor tyrosine kinase inhibitor lenvatinib mesylate will be presented during the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago, the United States, from June 1 to 5, 2018. more info >> |
|
| Monday, April 23, 2018 |
|
|
Eisai: Rights to Non-Opiod Severe Chronic Pain Treatment Prialt Transferred to Riemser |
| Eisai Co., Ltd. announced today that it has entered into an agreement to transfer the exclusive development and marketing rights for the non-opioid severe chronic pain treatment Prialt (ziconotide acetate) in Europe to Riemser Pharma GmbH. more info >> |
|
| Friday, April 20, 2018 |
|
|
Eisai to Present Latest Data on Perampanel and Rufinamide at Annual American Academy of Neurology Meeting |
| Eisai Co., Ltd. announced today that the latest data on its antiepileptic drugs (AED) perampanel and rufinamide will be presented at the 2018 Annual American Academy of Neurology (AAN) Meeting to be held from April 21 to 27, 2018 in Los Angeles, California in the United States. more info >> |
|
| Thursday, April 19, 2018 |
|
|
Eisai: World's First Bile Acid Transporter Inhibitor "GOOFICE 5mg Tablet" Launched in Japan |
| Eisai's subsidiary for gastrointestinal diseases EA Pharma Co., Ltd. and Mochida Pharmaceutical Co., Ltd. today announced that the bile acid transporter inhibitor "GOOFICE 5mg Tablet" was listed in Japan's National Health Insurance Drug Price List, and EA Pharma and Mochida launched the product onto Japan's market today. more info >> |
|
| Friday, April 13, 2018 |
|
|
Eisai Enters Into Joint Research Agreement With the Broad Institute, Colorado State University, and University of Chicago |
| Eisai Co., Ltd. announced today that it has entered into a joint research agreement with the Broad Institute, Mycobacteria Research Laboratories at Colorado State University, and the University of Chicago to develop a potential new treatment for tuberculosis (TB). more info >> |
|
| Monday, April 2, 2018 |
|
|
Eisai Submits Supplemental New Drug Application to U.S. FDA |
| Eisai Co., Ltd. has announced that it has submitted to the U.S. FDA a supplemental New Drug Application (sNDA) for Eisai's antiepileptic drug (AED) Fycompa (perampanel) seeking approval for an indication expansion to cover pediatric patients with epilepsy. more info >> |
|
| Wednesday, March 28, 2018 |
|
|
Eisai and Nichi-Iko Pharmaceutical Enter Into Strategic Alliance Agreement |
| Eisai Co., Ltd. and Nichi-Iko Pharmaceutical announced today that they have entered into a strategic alliance agreement as well as a share transfer agreement for a capital and business alliance. more info >> |
|
| Friday, March 23, 2018 |
|
|
AbbVie and Eisai Obtain Additional Approval for New Indication of Fully Human Anti-TNF-alpha Monoclonal |
| AbbVie GK and Eisai Co., Ltd. today announced the additional approval for a new indication of HUMIRA, a fully human anti-TNF-alpha monoclonal antibody formulation, in the treatment of patients who have had an inadequate response to conventional therapy for pustular psoriasis. With this approval, HUMIRA has been approved for 10 indications in Japan. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Local designer brands featured at 'Fashion Hong Kong Pop-up Salon' in Milan
Apr 3, 2025 08:00 HKT/SGT
|
|
|
Prideone Entertainment Announces New Post-War Film to Commemorate the 80th Anniversary of World War II's End
Apr 3, 2025 7:00 JST
|
|
|
3rd Future Cross Border Payments Summit, Dubai 2025: Trends Shaping the Future of Payments
Apr 2, 2025 22:03 HKT/SGT
|
|
|
Doubleview Gold Corp 2025 Exploration Program
Apr 2, 2025 21:00 HKT/SGT
|
|
|
Hola Prime Launches Industry-First One-on-One Mentorship from Market Experts 
Apr 2, 2025 20:00 HKT/SGT
|
|
|
Innovation Beverage Group Expands U.S. Distribution of its Award-Winning Bitters Through One of the Nation's Largest Beverage Alcohol Distributors
Apr 2, 2025 19:00 HKT/SGT
|
|
|
"GTF Advantage" Engine Achieved FAA Type Certification
Apr 2, 2025 17:41 JST
|
|
|
Expert Systems Expands Managed Services Offerings
Apr 2, 2025 16:33 HKT/SGT
|
|
|
Accelerated Transformation of New Quality Productive Forces with Growing Efficacy in Sci-Tech Innovation Layout
Apr 2, 2025 14:39 HKT/SGT
|
|
|
Euro Manganese Announces Upsize to Previously Announced Financing of up to C$11.2m (A$12.3m) including a Private Placement with Eric Sprott
Apr 2, 2025 14:10 HKT/SGT
|
|
|
CISO Indonesia 2025: Elevating Cybersecurity Strategies for a Resilient Digital Future
Apr 2, 2025 14:00 HKT/SGT
|
|
|
EdgePoint Towers Appoints Ravin Vickneswaran as Chief Operating Officer
Apr 2, 2025 11:00 HKT/SGT
|
|
|
Avenix Fzco Introduces Avexbot: Data-Driven Precision for Forex Traders
Apr 2, 2025 08:00 HKT/SGT
|
|
|
Wuling Motors (00305.HK) Achieves a Surge of 115.6% in Net Profit Attributable to Shareholders for 2024
Apr 1, 2025 21:53 HKT/SGT
|
|
|
Baguio Green Group Announces 2024 Annual Results
Apr 1, 2025 20:19 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
